CN102753199A - 癌干细胞标记物及其用途 - Google Patents
癌干细胞标记物及其用途 Download PDFInfo
- Publication number
- CN102753199A CN102753199A CN2011800065922A CN201180006592A CN102753199A CN 102753199 A CN102753199 A CN 102753199A CN 2011800065922 A CN2011800065922 A CN 2011800065922A CN 201180006592 A CN201180006592 A CN 201180006592A CN 102753199 A CN102753199 A CN 102753199A
- Authority
- CN
- China
- Prior art keywords
- cell
- stem cell
- cancer
- cancer stem
- tumor associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 652
- 201000011510 cancer Diseases 0.000 title claims abstract description 372
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 272
- 230000027455 binding Effects 0.000 claims abstract description 120
- 239000000427 antigen Substances 0.000 claims abstract description 107
- 108091007433 antigens Proteins 0.000 claims abstract description 107
- 102000036639 antigens Human genes 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 91
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 210000004027 cell Anatomy 0.000 claims description 396
- 235000000346 sugar Nutrition 0.000 claims description 186
- 150000008163 sugars Chemical class 0.000 claims description 181
- 239000003153 chemical reaction reagent Substances 0.000 claims description 164
- 230000000890 antigenic effect Effects 0.000 claims description 99
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 97
- 102100032912 CD44 antigen Human genes 0.000 claims description 96
- 206010006187 Breast cancer Diseases 0.000 claims description 58
- 208000026310 Breast neoplasm Diseases 0.000 claims description 57
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 57
- 102100040120 Prominin-1 Human genes 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 54
- 241001597008 Nomeidae Species 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 38
- 201000008275 breast carcinoma Diseases 0.000 claims description 31
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 28
- 230000001225 therapeutic effect Effects 0.000 claims description 27
- 210000004881 tumor cell Anatomy 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 24
- 238000002372 labelling Methods 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 23
- 238000012545 processing Methods 0.000 claims description 21
- 108090000288 Glycoproteins Proteins 0.000 claims description 18
- 102000003886 Glycoproteins Human genes 0.000 claims description 18
- 238000004043 dyeing Methods 0.000 claims description 17
- 238000004458 analytical method Methods 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 13
- 238000004393 prognosis Methods 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 12
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 11
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 11
- -1 multivalent antibody Proteins 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 102100034258 Sialomucin core protein 24 Human genes 0.000 claims description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 10
- 101001133085 Homo sapiens Sialomucin core protein 24 Proteins 0.000 claims description 9
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 8
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 7
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 7
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 7
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 7
- 230000003211 malignant effect Effects 0.000 claims description 7
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 230000030741 antigen processing and presentation Effects 0.000 claims description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 210000004882 non-tumor cell Anatomy 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 238000009792 diffusion process Methods 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- 230000004962 physiological condition Effects 0.000 claims description 5
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims description 4
- 230000005714 functional activity Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 201000001514 prostate carcinoma Diseases 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 208000012991 uterine carcinoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 150000001720 carbohydrates Chemical class 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000003550 marker Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 45
- 210000001519 tissue Anatomy 0.000 description 42
- 150000001413 amino acids Chemical group 0.000 description 30
- 230000000875 corresponding effect Effects 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 239000003999 initiator Substances 0.000 description 22
- 238000011160 research Methods 0.000 description 21
- 238000000684 flow cytometry Methods 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 229940098773 bovine serum albumin Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 229940126618 pankomab Drugs 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 12
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 12
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 210000005075 mammary gland Anatomy 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 9
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 238000003118 sandwich ELISA Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 229960001603 tamoxifen Drugs 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102000013415 peroxidase activity proteins Human genes 0.000 description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 description 7
- 229910052693 Europium Inorganic materials 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 6
- 208000011645 metastatic carcinoma Diseases 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
- 102000013275 Somatomedins Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 210000000270 basal cell Anatomy 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000012829 chemotherapy agent Substances 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000011503 in vivo imaging Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000013076 target substance Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000010185 immunofluorescence analysis Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000000505 pernicious effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 240000002825 Solanum vestissimum Species 0.000 description 2
- 235000018259 Solanum vestissimum Nutrition 0.000 description 2
- 102000015215 Stem Cell Factor Human genes 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000029565 malignant colon neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 229940060155 neuac Drugs 0.000 description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010005465 AC133 Antigen Proteins 0.000 description 1
- 102000005908 AC133 Antigen Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102000027791 CD44 antigen Human genes 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 101100351961 Caenorhabditis elegans pgp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- 150000008444 O-glycosides Chemical class 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000010220 Pearson correlation analysis Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710148833 Sialomucin core protein 24 Proteins 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000005179 adrenal carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 201000011050 comedo carcinoma Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013502 data validation Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 108010081954 galacto-N-biose Proteins 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29673810P | 2010-01-20 | 2010-01-20 | |
| EP10000527A EP2347769A1 (en) | 2010-01-20 | 2010-01-20 | Cancer stem cell markers and uses thereof |
| US61/296,738 | 2010-01-20 | ||
| EP10000527.1 | 2010-01-20 | ||
| PCT/EP2011/000217 WO2011089004A1 (en) | 2010-01-20 | 2011-01-20 | Cancer stem cell markers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102753199A true CN102753199A (zh) | 2012-10-24 |
Family
ID=42173400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800065922A Pending CN102753199A (zh) | 2010-01-20 | 2011-01-20 | 癌干细胞标记物及其用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120294859A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2347769A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2013517487A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102753199A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011208874B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012018132A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2786212A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011089004A1 (cg-RX-API-DMAC7.html) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103969437A (zh) * | 2014-04-22 | 2014-08-06 | 广州恒泰生物科技有限公司 | 用于卵巢癌早中期快速诊断试剂盒的制备方法 |
| CN111363008A (zh) * | 2020-03-18 | 2020-07-03 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原组合刺激培养的ctl细胞及其应用 |
| CN113804531A (zh) * | 2021-09-10 | 2021-12-17 | 北京大学 | 一种细胞高活性染色方法 |
| CN115916349A (zh) * | 2020-06-30 | 2023-04-04 | 葛莱高托普有限公司 | 针对Lewis Y的人源化抗体 |
| CN116718774A (zh) * | 2023-07-07 | 2023-09-08 | 杭州准星医学科技有限公司 | 一种用于肿瘤体外诊断的试剂盒及其使用方法 |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| ES2442024T3 (es) | 2008-07-15 | 2014-02-07 | Academia Sinica | Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| AU2011295722B2 (en) | 2010-09-03 | 2016-04-21 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2012039430A1 (ja) * | 2010-09-21 | 2012-03-29 | 株式会社Ｇｐバイオサイエンス | がん幹細胞の単離方法 |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| EP2972390B1 (en) | 2013-03-14 | 2017-11-08 | The United States Of America, As Represented By The Sectretary, Department Of Health And Human Services | Hyposialylation disorders |
| WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| EP3041484B1 (en) | 2013-09-06 | 2021-03-03 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
| HK1222569A1 (zh) | 2013-09-17 | 2017-07-07 | Obi Pharma, Inc. | 用於诱导免疫反应的糖疫苗组合物及其治疗癌症的用途 |
| JP2017507118A (ja) | 2014-01-16 | 2017-03-16 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | がんの処置および検出のための組成物および方法 |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| TWI687428B (zh) | 2014-03-27 | 2020-03-11 | 中央研究院 | 反應性標記化合物及其用途 |
| US10023651B2 (en) | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
| EP3797793A1 (en) * | 2014-04-18 | 2021-03-31 | The Research Foundation of the State University of New York at Buffalo | Humanized anti-tf-antigen antibodies |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR102512592B1 (ko) | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | 항-ｈｅｒ2 글리코항체 및 이의 용도 |
| EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| CA2950423A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| AU2015267044A1 (en) | 2014-05-28 | 2016-12-15 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
| WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
| CA2967595A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| CN107430127B (zh) * | 2015-01-24 | 2020-08-28 | 中央研究院 | 癌症标记及其使用方法 |
| KR102691114B1 (ko) | 2015-01-24 | 2024-08-01 | 아카데미아 시니카 | 신규한 글리칸 콘주게이트 및 이를 사용하는 방법 |
| US10493087B2 (en) | 2015-02-25 | 2019-12-03 | The United States of America, as represented by National Institute of Health | Sialylation-increasing therapies for diseases associated with oxidative stress |
| AR105910A1 (es) | 2015-09-04 | 2017-11-22 | Obi Pharma Inc | Matrices de glicano y método de uso |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2017100796A1 (en) * | 2015-12-11 | 2017-06-15 | SINACA, Academia | Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers |
| TW201808978A (zh) | 2016-03-08 | 2018-03-16 | 中央研究院 | N-聚醣及其陣列之模組化合成方法 |
| BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| TWI697333B (zh) | 2016-04-22 | 2020-07-01 | 台灣浩鼎生技股份有限公司 | 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法 |
| JP2019527690A (ja) | 2016-07-27 | 2019-10-03 | オービーアイ ファーマ，インコーポレイテッド | 免疫原性／治療用グリカン組成物およびその使用 |
| JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ，インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
| US10538592B2 (en) | 2016-08-22 | 2020-01-21 | Cho Pharma, Inc. | Antibodies, binding fragments, and methods of use |
| EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
| EP3543337B1 (en) * | 2016-11-18 | 2022-04-20 | Astellas Pharma Inc. | Novel anti-human muc1 antibody fab fragment |
| WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| JP2020510671A (ja) | 2017-03-03 | 2020-04-09 | シアトル ジェネティックス， インコーポレイテッド | グリカン相互作用化合物および使用の方法 |
| WO2018178047A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Multispecific antibody constructs binding to muc1 and cd3 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| CA3092470A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| PT110722B (pt) * | 2018-05-03 | 2021-08-17 | Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup | Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites |
| JP7360766B2 (ja) | 2018-05-17 | 2023-10-13 | アステラス製薬株式会社 | 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体 |
| US12479926B2 (en) | 2018-05-18 | 2025-11-25 | Daiichi Sankyo Co., Ltd. | Anti-MUC1 antibody-drug conjugate |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| JP7374544B2 (ja) | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN110161241A (zh) * | 2019-04-30 | 2019-08-23 | 丁晓昆 | 一种快速检测生物组织切片cosmc基因突变试剂盒 |
| CA3166533A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| JP2023509442A (ja) | 2020-01-03 | 2023-03-08 | インサイト・コーポレイション | Ｃｄ７３阻害剤とａ２ａ／ａ２ｂアデノシン受容体阻害剤の併用療法 |
| AU2021411952A1 (en) | 2020-12-29 | 2023-08-10 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
| CA3224907A1 (en) * | 2021-07-16 | 2023-03-02 | Claude Perreault | Novel tumor-specific antigens for cancer stem cells and uses thereof |
| CN119955728A (zh) * | 2022-08-01 | 2025-05-09 | 首都医科大学附属北京胸科医院 | 恶性表型大细胞肺癌细胞株及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020192223A1 (en) * | 1989-06-30 | 2002-12-19 | Ingegerg Hellstrom | Novel antibody conjugates reactive with human carcinomas |
| US20060251668A1 (en) * | 2002-11-29 | 2006-11-09 | Steffen Goletz | Tumor-specific recognition molecules |
| US7374755B2 (en) * | 2004-07-26 | 2008-05-20 | The Research Foundation Of State University Of New York | Therapeutic use of anti-TF-Antigen antibody |
| US20090041836A1 (en) * | 2006-01-03 | 2009-02-12 | University Of Georgia Research Foundation, Inc. | Glycolipopeptide and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1654353B1 (en) | 2003-08-18 | 2013-05-22 | Glycotope GmbH | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof |
| WO2007140011A2 (en) * | 2006-05-26 | 2007-12-06 | The Government Of The United States Of America | Erythroid progenitor cells and methods for producing parvovirus b19 therein |
-
2010
- 2010-01-20 EP EP10000527A patent/EP2347769A1/en not_active Withdrawn
-
2011
- 2011-01-20 BR BR112012018132A patent/BR112012018132A2/pt active Search and Examination
- 2011-01-20 CN CN2011800065922A patent/CN102753199A/zh active Pending
- 2011-01-20 CA CA2786212A patent/CA2786212A1/en not_active Abandoned
- 2011-01-20 JP JP2012549291A patent/JP2013517487A/ja not_active Ceased
- 2011-01-20 AU AU2011208874A patent/AU2011208874B2/en not_active Ceased
- 2011-01-20 WO PCT/EP2011/000217 patent/WO2011089004A1/en not_active Ceased
- 2011-01-20 EP EP11703580A patent/EP2525832A1/en not_active Withdrawn
- 2011-01-20 US US13/574,260 patent/US20120294859A1/en not_active Abandoned
-
2015
- 2015-12-25 JP JP2015253064A patent/JP2016047848A/ja not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020192223A1 (en) * | 1989-06-30 | 2002-12-19 | Ingegerg Hellstrom | Novel antibody conjugates reactive with human carcinomas |
| US20060251668A1 (en) * | 2002-11-29 | 2006-11-09 | Steffen Goletz | Tumor-specific recognition molecules |
| US7374755B2 (en) * | 2004-07-26 | 2008-05-20 | The Research Foundation Of State University Of New York | Therapeutic use of anti-TF-Antigen antibody |
| US20090041836A1 (en) * | 2006-01-03 | 2009-02-12 | University Of Georgia Research Foundation, Inc. | Glycolipopeptide and uses thereof |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103969437A (zh) * | 2014-04-22 | 2014-08-06 | 广州恒泰生物科技有限公司 | 用于卵巢癌早中期快速诊断试剂盒的制备方法 |
| CN111363008A (zh) * | 2020-03-18 | 2020-07-03 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原组合刺激培养的ctl细胞及其应用 |
| CN113388023A (zh) * | 2020-03-18 | 2021-09-14 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| CN113429473A (zh) * | 2020-03-18 | 2021-09-24 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| CN111363008B (zh) * | 2020-03-18 | 2021-11-16 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原组合刺激培养的ctl细胞及其应用 |
| CN113429473B (zh) * | 2020-03-18 | 2022-11-04 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| CN115916349A (zh) * | 2020-06-30 | 2023-04-04 | 葛莱高托普有限公司 | 针对Lewis Y的人源化抗体 |
| US12415864B2 (en) | 2020-06-30 | 2025-09-16 | Pentixapharm Ag | Humanized antibodies against Lewis Y |
| CN113804531A (zh) * | 2021-09-10 | 2021-12-17 | 北京大学 | 一种细胞高活性染色方法 |
| CN113804531B (zh) * | 2021-09-10 | 2024-02-06 | 北京大学 | 一种细胞高活性染色方法 |
| CN116718774A (zh) * | 2023-07-07 | 2023-09-08 | 杭州准星医学科技有限公司 | 一种用于肿瘤体外诊断的试剂盒及其使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013517487A (ja) | 2013-05-16 |
| EP2525832A1 (en) | 2012-11-28 |
| WO2011089004A1 (en) | 2011-07-28 |
| CA2786212A1 (en) | 2011-07-28 |
| US20120294859A1 (en) | 2012-11-22 |
| EP2347769A1 (en) | 2011-07-27 |
| AU2011208874B2 (en) | 2015-06-25 |
| AU2011208874A1 (en) | 2012-08-02 |
| JP2016047848A (ja) | 2016-04-07 |
| BR112012018132A2 (pt) | 2017-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102753199A (zh) | 癌干细胞标记物及其用途 | |
| Nishiwada et al. | Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer | |
| Oak et al. | Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2‐positive cancer cells and cancer stem cells | |
| JP5689133B2 (ja) | 結腸直腸癌におけるｐｏｄｘｌタンパク質 | |
| JP6795813B2 (ja) | がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物 | |
| Lin et al. | Expression of CD176 (Thomsen‐Friedenreich antigen) on lung, breast and liver cancer‐initiating cells | |
| JPWO2008056833A1 (ja) | ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体 | |
| CN108064343B (zh) | 用于前列腺癌分析的组合物和方法 | |
| JPWO2009116670A1 (ja) | ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体 | |
| RU2641968C2 (ru) | Композиции и способы анализа рака предстательной железы | |
| JP2020125352A (ja) | 抗−ｃｄ４３抗体およびその癌治療用途 | |
| Okamura et al. | Superficially located enlarged lymphoid follicles characterise nodular gastritis | |
| CN101553259A (zh) | 显示cd63表面表达的细胞的细胞毒性介导 | |
| Glumac et al. | The identification of a novel antibody for CD133 using human antibody phage display | |
| JP2019528437A (ja) | 腫瘍関連マクロファージをターゲティングすることによるガン疾患の処置方法 | |
| KR101374758B1 (ko) | 항-사이토케라틴 8/18 복합체 자가면역항체를 포함하는 암 진단 마커 및 이의 항원을 포함하는 암 진단용 조성물 | |
| Lin et al. | Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells | |
| US9206258B2 (en) | Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same | |
| JP5711877B2 (ja) | 癌の悪性度の検知方法及び癌の悪性度の診断剤 | |
| WO2025026204A1 (en) | Antibodies against ror1 and uses thereof | |
| US20130143231A1 (en) | MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY | |
| WO2020171171A1 (ja) | 抗ｈｌａ－ｄｒ抗体、およびそのがん治療用途 | |
| HK1255484A1 (en) | Compositions and methods for prostate cancer analysis | |
| HK1255484B (en) | Compositions and methods for prostate cancer analysis | |
| JP2011001267A (ja) | 大腸癌治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121024 |